Company Analysis
Sign in

Generate Biomedicines, Inc. (GENB)

Nasdaq: GENB · Pharmaceutical Preparations · filing with the SEC since 2025
Full chart Alerts Compare
Grade5.8
◀ Past 6.0● Present 6.7▶ Future 5.0
8 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

1 patent granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Generate Biomedicines, Inc.’s names, not what it holds today.

Patents granted
1
1 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and none in 2023
Applications published
6
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Generate Biomedicines, Inc. its own name
named as the applicant on its applications, in US
0 granted
6 published
Generate Biomedicines, Inc. its own name
US, as the owner printed on each patent
1 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
May 28, 202411,993,644Antigen binding molecules targeting SARS-CoV-2PharmaceuticalsGenerate Biomedicines, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jul 3, 20252025/0218530DIFFUSION MODEL FOR GENERATIVE PROTEIN DESIGNComputer technologyGenerate Biomedicines, Inc.
Dec 5, 20242024/0404123IMAGE GENERATION WITH FLEXIBLE SAMPLER FOR DIFFUSION MODELINGComputer technologyGenerate Biomedicines, Inc.
Oct 31, 20242024/0360203Antigen Binding Molecules Targeting SARS-CoV-2PharmaceuticalsGenerate Biomedicines, Inc.
May 16, 20242024/0161864DIFFUSION MODEL FOR GENERATIVE PROTEIN DESIGNComputer technologyGenerate Biomedicines, Inc.
Nov 9, 20232023/0357367Antigen Binding Molecules Targeting SARS-CoV-2PharmaceuticalsGenerate Biomedicines, Inc.
Nov 9, 20232023/0357366Antigen Binding Molecules Targeting SARS-CoV-2PharmaceuticalsGenerate Biomedicines, Inc. · patent 11,993,644 granted from it
What it applied for, 2024 to 2025: Computer technology 3 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton GENB · research, not advice